Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Withdrawn 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1

Conditions

Prostatic Neoplasms 1Leukemia, Myelomonocytic, Acute 1Leukemia, Myeloid, Acute 1Leukemia, Monocytic, Acute 1Leukemia, Megakaryoblastic, Acute 1Leukemia, Erythroblastic, Acute 1Leukemia 1

Interventions

Cytarabine 23Busulfan 12Peripheral Blood Stem Cell Transplantation 11Cyclophosphamide 10fludarabine phosphate 9Filgrastim 9Cyclosporine 9Antilymphocyte Serum 9Idarubicin 8Methotrexate 7sargramostim 6Mitoxantrone 6Gemtuzumab 6Etoposide 6Daunorubicin 6Radiotherapy 5tipifarnib 4Whole-Body Irradiation 4alvocidib 3Vorinostat 3Tacrolimus 3Mycophenolic Acid 3Methylprednisolone 3Flow Cytometry 3Cytogenetic Analysis 3Cyclosporins 3Clofarabine 3Azacitidine 3merphos 2Topotecan 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Leukemia, Megakaryoblastic, Acute × Bromodeoxyuridine × Clear all
NCT00003405 2021-10-14

Combination Chemotherapy Plus Biological Therapy in Treating Patients With Acute Myelogenous Leukemia

Rush University Medical Center

Phase 2 Withdrawn
Other hematologic neoplasm

Leukemia, Erythroblastic, Acute, Leukemia, Leukemia, Megakaryoblastic, Acute, Leukemia, Monocytic, Acute, Leukemia, Myeloid, Acute, Leukemia, Myelomonocytic, Acute

Data powered by HemOnc (CC BY 4.0) Colophon âš¡